Picankibart Biosimilar - Research Grade

Human

IL23Aï؟½

5mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Q9NPF7

Blue ice

Interleukin-23 subunit p19 (IL23A) drives Th17-axis inflammation and is a validated target across autoimmune research. This human IgG1 kappa antibody is an unconjugated, non-therapeutic analog of picankibart, generated in CHO cells against human IL23A. For research use only, it is purified to low endotoxin for in vivo compatibility and supplied in scalable milligram (mg) to gram (g) quantities for bulk and high-throughput laboratories. It serves as a dependable reagent for cytokine-neutralization assays, signaling studies, functional readouts, and preclinical models of psoriasis and inflammatory bowel disease. It delivers the consistency that bulk-consuming research programs require.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks